Expression of the multidrug resistance-associated protein in myelodysplastic syndromes

British Journal of Haematology

Volumn 110, Issue 3, 2000, Pages 591-598

  Poulain, Stéphanie ^a   Lepelley, Pascale ^a   Preudhomme, Claude ^a   Cambier, Nathalie ^a   Cornillon, Jérome ^a   Wattel, Eric ^a   Cosson, Alain ^a   Fenaux, Pierre ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Functional test; MRP1; Multidrug resistance; Myelodysplastic syndromes; P glycoprotein

Indexed keywords

CALCEIN; CD34 ANTIGEN; CYTARABINE; DOXORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PROBENECID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FLOW CYTOMETRY; FUNCTION TEST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033776858     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02247.x     Document Type: Article

References (39)

1. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines
2. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: Consensus recommendations
3. Expression of the multidrug resistance associated protein (MRP) in acute and chronic leukemias
4. Multidrug resistance associated with overexpression of MRP
5. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
6. Pharmacological characterisation of multidrug resistant MRP-transfected human tumor cells
7. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells
8. Kinetic analysis of calcein and calcein-acetomethylester efflux mediated by the multidrug-resistant protein and P-glycoprotein
9. MRP expression in acute myeloid leukemia has no impact on treatment outcome
10. MRP expression in acute myeloid leukemia. An update
11. Tissue distribution of the Multidrug Resistance Protein
12. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells
13. Biochemistry of multidrug resistance mediated by the multidrug transporter
14. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia
15. Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP)
16. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
17. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
18. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay
19. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haematopoietic cells
20. P-gp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
21. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
22. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR1-/efflux+ and MDR1+/efflux-cases
23. Acute myeloid leukemia in the ederly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroups with remarkebly distinct responses to standard chemotherapy. A Southwest Oncology Group study
24. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study
25. Expression of multidrug resistance P-Glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes
26. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes
27. Multidrug resistance (MDR1) gene expression in adult acute leukemias: Correlation with treatment outcome and in vitro drug sensitivity
28. Multicentric evaluation of the MDR phenotype in leukemia
29. P-glycoprotein (P-gp) and lung resistance-related protein (LRP) expression and function in leukeamic blasts cells
30. Assessement of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia
31. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia patients
32. 1 110.000 vesicular protein in non P-Glycoprotein mediated multidrug
33. Increased expression of the multidrug resistance associated protein gene in relapsed acute leukemia
34. + peripheral cells
35. On the relationship between the probenecid sensitive transport of daunorubicin or calcein and the glutathione status of cells over expressing the multidrug resistance-associated protein (MRP)
36. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-Glycoprotein: Results of a randomized study
37. Discordant P-glycoprotein antigen and transport function in acute myeloid leukemia
38. Glutathione-related mechanisms in cellular resistance to anticancer drugs
39. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute leukemia